Pharmamarketeer

AveXis’s gene therapy Zolgensma receives US FDA approval to treat paediatric patients with SMA

AveXis, a Novartis company, announced the US Food and Drug Administration (FDA) has approved Zolgensma (onasemnogene abeparvovec─xioi) for the treatment of paediatric patients less than 2 years of age

Medhc-fases-banner
Advertentie(s)